Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
giovedì, ottobre 08
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Neurogene Inc
NGNE
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$25.87
0.42
1.65%
Ult. Agg.: Oct 7, 4:00 PM
$25.87
0.42
1.65%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Neurogene Financials
Neurogene (NGNE) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Neurogene Q2 EPS $(1.53) Misses $(1.39) Estimate
Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.53) per share which missed the analyst consensus estimate of $(1.39) by 10.07 percent. This is a 45.71 percent decrease over losses of $(1.05) per share from the
Benzinga Newsdesk
PRO
Neurogene Q1 EPS $(1.39) Misses $(1.36) Estimate
Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(1.36) by 2.21 percent. This is a 28.7 percent decrease over losses of $(1.08) per share from the
Benzinga Newsdesk
PRO
Neurogene Q4 EPS $(1.13), Inline
Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.13) per share which met the analyst consensus estimate. This is a 13 percent decrease over losses of $(1.00) per share from the same period last year.
Benzinga Newsdesk
PRO
Neurogene Q3 EPS $(0.99) Beats $(1.25) Estimate
Benzinga Newsdesk
PRO
Neurogene Q2 EPS $(1.05) Beats $(1.16) Estimate
Benzinga Newsdesk
PRO
Neurogene Q1 EPS $(1.08), Inline
Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.08) per share which met the analyst consensus estimate. This is a 8 percent decrease over losses of $(1.00) per share from the same period last year.
Benzinga Newsdesk
